Assay development optimisation & technology

#Assay development optimisation & technology #Clinical specialities #High Content Screening #Immunology #PCR #RNA

Sino Biological partners with Nanommune to develop coronavirus multiplex serological assay

Sino Biologica has announced a co-development agreement with Nanommune, an Irvine, California-based biotechnology company specialising in the development and application of multiplex array technology. Under the terms of the agreement, the two companies will jointly develop coronavirus antigen array products for serological studies of COVID-19 and other infectious… Read More

#Covid-19 #News

#Analysis #Analytical chemistry #Assay development optimisation & technology #Biochemistry #Biomarkers #Business #Cell / tissue culture #Cellular assays #Chemical engineering #Chemistry #Clinical specialities #Genetics / genomics #Imaging #Lead discovery #Mass spectrometry / NMR #Molecular medicine #Pathology #Pharmacology #Precision medicine #Protein chemistry / Proteomics #Regulatory #RNA #Stem cells #System biology #Target validation #Therapeutics #Translational #Translational chemistry

Innovative glycan imaging methods drive cancer biomarker discovery

Innovative glycan imaging methods drive cancer biomarker discovery By Dr Richard Drake, Dr Anand Mehta and Dr Peggy Angel Volume 21 Issue 2 – Spring 2020 Glycosylation accounts for the majority of post-translational modifications (PTMs) of proteins, and changes in glycosylation are known to play a key role… Read More

#Exclusive Content

#Academic #ADME / Tox #AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Biochemistry #Business #Chemical engineering #Chemistry #Clinical trials #Computational chemistry #Drug development #Drug discovery #Drug targets #Gene therapy #High Content Screening #High throughput screening #Lead discovery #Medicinal chemistry #Organic chemistry #RNA #Screening #System biology #Systems biology #Toxicology #Translational #Translational chemistry

How sharing compound solubility data can advance drug discovery

By Andrii Lozoniuk Volume 21 Issue 2 – Spring 2020 Gathering compound solubility data is a key step during drug discovery that helps ensure cost-effective screening, yet it is a long process and is often underestimated in terms of difficulty. Global sharing of such data can… Read More

#Exclusive Content

#AI / data analytics / healthtech / informatics #Analysis #Analytical chemistry #Assay development optimisation & technology #Biochemistry #Biomarkers #Business #Cell therapy #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Gene editing #Gene therapy #Genetics / genomes #Genetics / genomics #Genomics #High Content Screening #High throughput screening #Imaging #Immunology / Virology & Vaccines #Mass spectrometry / NMR #Metabolomics #Molecular medicine #Oncology #Pharmacogenomics #Pharmacology #Precision medicine #Protein chemistry / Proteomics #Regulatory #RNA #Screening #Sequencing #Stem cells #System biology #Systems biology #Target validation #Therapeutics #Toxicology #Translational #Translational chemistry #Urinary

Harnessing the modified proteome for increased diagnostic power

Harnessing the modified proteome for increased diagnostic power By Dr David Bramwell, Dr Steven Laval and Dr Jane McLeod Relevant biomarkers are vitally important in personalised medicine, guiding patient matching to specific therapies for earlier, easier and more effective disease identification and treatment. Here we trace… Read More

#Archive

#ADME / Tox #AI / data analytics / healthtech / informatics #Analysis #Assay development & optimisation #Assay development optimisation & technology #Automation / robotics #Business #Cellular & Molecular biology #Cellular assays #Drug development #Drug discovery #Enabling technologies #Gene editing #Genomics #High Content Screening #High throughput screening #Immunology #Lead discovery #Lead optimisation #Protein chemistry / Proteomics #Screening #Target validation #Toxicology

Getting a handle on liquids: automation solutions for drug discovery

Getting a handle on liquids: automation solutions for drug discovery By Helen Stewart-Miller and Thomas Hope The accurate and precise measurement of liquids and the transport of exact volumes between vessels, or from one instrument to another, are processes that constitute the very essence of research. Read More

#Archive

#ADME / Tox #AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Automation / robotics #Business #Cell / tissue culture #Cell culture #Cellular & Molecular biology #Cellular assays #Drug development #Drug discovery #Enabling technologies #High Content Screening #High throughput screening #Imaging #Lead discovery #Molecular medicine #Oncology #Pharmacology #RNA #Screening #Stem cells #System biology #Systems biology #Target validation #Toxicology

Using Live-Cell Imaging Systems to Transform Perspectives in Drug Discovery

Using Live-Cell Imaging Systems to Transform Perspectives in Drug Discovery By Helen Stewart-Miller and Dr Kate Tointon Live-cell imaging has transformed the study of cell behaviour and function. The technique allows researchers to monitor internal cell structures, interactions and processes in real-time, and over time. In… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Automation / robotics #Biomarkers #Business #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Enabling technologies #Genomics #High Content Screening #High throughput screening #Lead discovery #Oncology #Regulatory #Screening #Sequencing #System biology #Systems biology #Therapeutics #Translational #Translational chemistry

Unlocking Clinical Trial Data to Uncover New Therapeutic Opportunities

Unlocking Clinical Trial Data to Uncover New Therapeutic Opportunities By David Wang, Masha Hoffey and Dr Simone Sharma This article discusses opportunities, challenges and best practices in leveraging infrastructure excellence and AI to unlock the value of early or inconclusive clinical trial data. The goal… driving stronger biomarker-based… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Assay development optimisation & technology #Automation / robotics #Biochemistry #Business #Chemistry #Drug development #Drug discovery #Drug targets #High Content Screening #High throughput screening #Immunology #Immunology / Virology & Vaccines #Lead discovery #Lead optimisation #Medicinal chemistry #Molecular medicine #Oncology #Pharmokinetics #RNA #Screening #Sequencing #System biology #Target validation

Reducing the PAINS in High Throughput Screening

Reducing the PAINS in High Throughput Screening: Assay design as a tool for maximising efficiency By Dr Philip S. Jones and Dr Stuart P. McElroy While the quality of the compound collection is frequently described as a key determinant of the success of a high throughput screening… Read More

#Archive

#Academic #ADME / Tox #AI / data analytics / healthtech / informatics #Analysis #Analytical chemistry #Assay development optimisation & technology #Automation / robotics #Biochemistry #Biomarkers #Business #Cell / tissue culture #Cell culture #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Drug development #Drug discovery #Drug targets #Enabling technologies #Genomics #High Content Screening #High throughput screening #Imaging #Lead discovery #Lead optimisation #Medicinal chemistry #Microfluidics #Molecular medicine #Pathology #Pharmacology #Precision medicine #Preclinical #Protein chemistry / Proteomics #Regulatory #RNA #Screening #Sequencing #Stem cells #System biology #Systems biology #Toxicology

Optimising Phenotypic Screening – Single-cell analysis versus 3D multicell analysis

Optimising Phenotypic Screening – Single-cell analysis versus 3D multicell analysis By Dr Richard M. Eglen In light of the high failure rate of compounds when they are subjected to clinical testing, we are seeing a renaissance in phenotypic screening in drug discovery. However, most phenotypic screening is… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Animal models #Assay development optimisation & technology #Business #Cell / tissue culture #Cell culture #Cellular & Molecular biology #Cellular assays #Chemical engineering #Clinical specialities #Clinical trials #Drug development #Drug discovery #Enabling technologies #High Content Screening #High throughput screening #Imaging #Lead discovery #Microbiome #Oncology #Pharmokinetics #Preclinical #RNA #Screening #Sequencing #Stem cells #System biology #Systems biology #Therapeutics #Toxicology

Evolving Models for NASH Drug Discovery: Tools for stemming a silent epidemic

Evolving Models for NASH Drug Discovery: Tools for stemming a silent epidemic By Dr Sue Grepper, Dr Radina Kostadinova, Dr Eva Thoma and Professor Armin Wolf Non-alcoholic fatty liver disease (NAFLD) has quietly become one of the most common causes of chronic liver disease in the modern world. Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Biologics / Biotechnology #Business #Cell / tissue culture #Cell culture #Cell therapy #Cellular & Molecular biology #Cellular assays #Drug development #Drug discovery #Drug targets #Gene editing #Gene therapy #Genetics / genomes #Genomics #High Content Screening #High throughput screening #Immunology #In Silico Biology #Lead discovery #Lead optimisation #Molecular medicine #Oncology #Orphan drugs #Pathology #Pharmacology #Preclinical #Protein chemistry / Proteomics #Regulatory #RNA #Screening #Sequencing #Stem cells #System biology #Systems biology #Target validation

Fail Early, Fail Fast – A phenotypic rescue approach

Fail Early, Fail Fast – A phenotypic rescue approach By Dr Anne-Marie Zuurmond, et al. New disease targets frequently emerge in literature, but the thorough target validation required to consider these targets for a drug discovery programme is often lacking. In pharmacological or genetic perturbation studies… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Assay development & optimisation #Assay development optimisation & technology #Automation / robotics #Biomarkers #Business #Cell culture #Cellular & Molecular biology #Cellular assays #Chemistry #Combinatorial chemistry #Computational chemistry #Drug development #Drug discovery #Drug targets #Gene editing #Genetics / genomes #Genomics #High Content Screening #High throughput screening #Imaging #In Silico Biology #Lead discovery #Medicinal chemistry #Molecular medicine #Oncology #Organic chemistry #Pathology #Precision medicine #Protein chemistry / Proteomics #RNA #Screening #Sequencing #Stem cells #System biology #Systems biology #Target validation #Therapeutics

Automating Automation – How close are we to Artificial Intelligence impact?

Automating Automation – How close are we to Artificial Intelligence impact? By Dr Michael A. Tarselli, Dr Yohann Potier and Dr Alan E. Fletcher In terms of consistency, repeatability, known errors and sheer volume, there exists perhaps no better collection of data for computer learning than that… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Biomarkers #Business #Cell therapy #Cellular & Molecular biology #Clinical specialities #Clinical trials #Drug development #Drug discovery #Enabling technologies #Gene therapy #Genetics / genomes #Genetics / genomics #Genomics #In Silico Biology #Lead discovery #Lead optimisation #Molecular medicine #Precision medicine #Regulatory #RNA #Sequencing #Stem cells #System biology #Systems biology #Therapeutics #Toxicology

Application of bioinformatics in support of precision medicine

Application of bioinformatics in support of precision medicine By Mike Furness and John Wise Bioinformatics has played a major role in gene sequencing diagnostics and has been an essential tool to investigate the genetic causes of disease. With the support of new technologies and tools, bioinformatics can play… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Animal models #Assay development optimisation & technology #Automation / robotics #Business #Cell / tissue culture #Cell culture #Cellular assays #Drug development #Drug discovery #Drug targets #Enabling technologies #Genetics / genomes #High Content Screening #High throughput screening #Imaging #Lead discovery #Oncology #Precision medicine #Protein chemistry / Proteomics #Screening #Stem cells #System biology #Systems biology #Toxicology

Automated Cell-based Assays: Novel tools overcome the barriers to discovery success

Automated Cell-based Assays: Novel tools overcome the barriers to drug discovery success By Helen Stewart-Miller and Kate Tointon In this article, we look at how commercial products and services are facilitating the automation of cell-based assays to advance drug discovery and accelerate the delivery of new medicines to… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Animal models #Assay development optimisation & technology #Automation / robotics #Biochemistry #Biologics / Biotechnology #Biomarkers #Business #Chemical engineering #Chemistry #Clinical specialities #Clinical trials #Computational chemistry #Drug development #Drug discovery #High Content Screening #Lead discovery #Lead optimisation #Molecular medicine #Oncology #Orphan drugs #Pharmacology #Precision medicine #Preclinical #QA/QC #Regulatory #RNA #System biology #Systems biology #Toxicology #Translational #Translational chemistry

The Reality of Virtual Pharmaceutical Companies

The Reality of Virtual Pharmaceutical Companies By Dr Stephen Naylor and Dr Kirkwood A. Pritchard Jr We discuss the oxymoronic proposition of a Virtual Pharmaceutical Company (VPC) and the typical adopted business model, as well as provide examples of such companies currently trying to undertake this adventurous… Read More

#Archive

#Analysis #Assay development optimisation & technology #Automation / robotics #Business #Cell culture #Cellular assays #Chemical engineering #Clinical specialities #Drug development #Drug discovery #High throughput screening #Lead discovery #Lead optimisation #Regulatory #RNA #Screening #Stem cells

Safety First – Automating cell line development

Safety First – Automating cell line development By Jon Newman-Smith Developing and maintaining cell cultures in a stable and sterile environment is of paramount importance to protect samples and increase overall success of drug discovery pipelines. Cell lines are extremely fragile and susceptible to contamination which can be… Read More

#Archive